BioLineRx (NASDAQ:BLRX) Earns Buy Rating from HC Wainwright

HC Wainwright reiterated their buy rating on shares of BioLineRx (NASDAQ:BLRX) in a report published on Wednesday, Benzinga reports. HC Wainwright currently has a $21.00 price target on the biotechnology company’s stock.

Separately, StockNews.com upgraded shares of BioLineRx to a sell rating in a report on Friday, April 12th.

BioLineRx Price Performance

NASDAQ BLRX opened at $0.62 on Wednesday. BioLineRx has a 12 month low of $0.61 and a 12 month high of $2.53. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.53 and a quick ratio of 1.47. The firm has a market capitalization of $49.74 million, a PE ratio of -0.69 and a beta of 1.38. The company’s 50 day simple moving average is $1.08 and its 200 day simple moving average is $1.34.

BioLineRx (NASDAQ:BLRX) last posted its quarterly earnings data on Thursday, March 28th. The biotechnology company reported ($0.15) EPS for the quarter, beating analysts’ consensus estimates of ($0.22) by $0.07. The company had revenue of $4.80 million for the quarter, compared to analyst estimates of $0.17 million. During the same quarter in the prior year, the business earned ($0.09) EPS. As a group, equities research analysts forecast that BioLineRx will post -1.03 EPS for the current fiscal year.

Hedge Funds Weigh In On BioLineRx

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. LPL Financial LLC boosted its stake in BioLineRx by 6.4% in the 2nd quarter. LPL Financial LLC now owns 125,210 shares of the biotechnology company’s stock worth $200,000 after purchasing an additional 7,500 shares during the period. B. Riley Wealth Advisors Inc. lifted its position in BioLineRx by 88.5% in the 3rd quarter. B. Riley Wealth Advisors Inc. now owns 21,300 shares of the biotechnology company’s stock worth $39,000 after buying an additional 10,000 shares in the last quarter. Geneos Wealth Management Inc. lifted its position in BioLineRx by 72.3% in the 3rd quarter. Geneos Wealth Management Inc. now owns 40,500 shares of the biotechnology company’s stock worth $74,000 after buying an additional 17,000 shares in the last quarter. NorthRock Partners LLC purchased a new stake in BioLineRx in the 4th quarter worth approximately $27,000. Finally, Renaissance Technologies LLC lifted its position in BioLineRx by 49.1% in the 3rd quarter. Renaissance Technologies LLC now owns 68,222 shares of the biotechnology company’s stock worth $63,000 after buying an additional 22,478 shares in the last quarter. Institutional investors and hedge funds own 1.56% of the company’s stock.

BioLineRx Company Profile

BioLineRx Ltd., a pre-commercial-stage biopharmaceutical company, focuses on oncology. The company develops Motixafortide, a peptide, which has completed Phase 3 clinical trials for the treatment of autologous stem cell mobilization and Phase 2a clinical trials for the treatment of pancreatic cancer; and that is in Phase 2 clinical trials for the treatment of metastatic pancreatic adenocarcinoma patients, and Phase 1b clinical trials in patients with acute respiratory distress syndrome secondary to COVID-19 and other respiratory viral infections, as well as for the treatment of solid tumors and acute myeloid leukemia.